Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Rick Winningham Sells 2,741 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Rick Winningham sold 2,741 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $241.57, for a total value of $662,143.37. Following the sale, the director directly owned 9,567 shares of the company’s stock, valued at approximately $2,311,100.19. The trade was a 22.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $237.56 on Thursday. The stock has a 50 day simple moving average of $205.91 and a 200 day simple moving average of $182.44. Jazz Pharmaceuticals PLC has a 1-year low of $105.00 and a 1-year high of $243.32. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95. The stock has a market cap of $14.90 billion, a P/E ratio of -11,872.06, a PEG ratio of 0.42 and a beta of 0.27.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The firm had revenue of $1.07 billion for the quarter. Research analysts anticipate that Jazz Pharmaceuticals PLC will post 20.75 earnings per share for the current year.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Hilltop National Bank bought a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at $36,000. LRI Investments LLC bought a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at $38,000. Danske Bank A S bought a new position in shares of Jazz Pharmaceuticals in the 3rd quarter valued at $40,000. Geneos Wealth Management Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 137 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in shares of Jazz Pharmaceuticals by 1,383.3% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 332 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on JAZZ shares. Morgan Stanley restated an “overweight” rating and set a $245.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, May 7th. Wells Fargo & Company raised their price objective on Jazz Pharmaceuticals from $250.00 to $265.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Truist Financial upgraded Jazz Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Royal Bank Of Canada raised their price objective on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Finally, Weiss Ratings upgraded Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $242.65.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.